Published in Medicine (Baltimore) on November 01, 1996
Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) | NCT00000586
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A (2002) 2.72
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood (1999) 2.66
Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest (2007) 2.47
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med (2008) 2.31
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood (2011) 1.54
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci U S A (1998) 1.20
Sickle red cell-endothelium interactions. Microcirculation (2009) 1.12
Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes (2006) 1.11
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica (2010) 1.10
Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice. Am J Physiol Regul Integr Comp Physiol (2009) 1.08
Imaging flow cytometry for automated detection of hypoxia-induced erythrocyte shape change in sickle cell disease. Am J Hematol (2014) 1.07
Current therapy of sickle cell disease. Haematologica (2006) 1.03
The rationale for using hydroxycarbamide in the treatment of sickle cell disease. Haematologica (2011) 1.01
Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results. J Natl Med Assoc (2001) 0.99
The role of infection in the pathogenesis of vaso-occlusive crisis in patients with sickle cell disease. Mediterr J Hematol Infect Dis (2011) 0.96
Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood (2016) 0.96
Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer (2012) 0.93
Antisickling fetal hemoglobin reduces hypoxia-inducible factor-1α expression in normoxic sickle mice: microvascular implications. Am J Physiol Heart Circ Physiol (2012) 0.93
Autosplenectomy in severity of sickle cell diseases. Int J Clin Exp Med (2014) 0.91
Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints. Int J Environ Res Public Health (2009) 0.90
Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease. Haematologica (2010) 0.90
Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics (2014) 0.89
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood (2016) 0.87
Nucleosomes and neutrophil activation in sickle cell disease painful crisis. Haematologica (2013) 0.84
Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica (2013) 0.84
Sickle cell diseases: current therapeutic options and potential pitfalls in preventive therapy for transcranial Doppler abnormalities. Pediatr Radiol (2005) 0.83
The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease. Blood Cells Mol Dis (2011) 0.81
Integrating interactive web-based technology to assess adherence and clinical outcomes in pediatric sickle cell disease. Anemia (2012) 0.80
Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity in Sickle Cell Disease. J Pain (2015) 0.80
Detailed mechanism of the autoxidation of N-hydroxyurea catalyzed by a superoxide dismutase mimic Mn(III) porphyrin: formation of the nitrosylated Mn(II) porphyrin as an intermediate. Dalton Trans (2012) 0.79
Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease. PLoS One (2016) 0.78
Hydroxyurea therapy mobilises arachidonic Acid from inner cell membrane aminophospholipids in patients with homozygous sickle cell disease. J Lipids (2011) 0.77
Biomechanics and biorheology of red blood cells in sickle cell anemia. J Biomech (2016) 0.76
Biomarkers and recent advances in the management and therapy of sickle cell disease. F1000Res (2015) 0.75
Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease. Am J Prev Med (2016) 0.75
Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia. PLoS One (2015) 0.75
Dissecting the energies that stabilize sickle hemoglobin polymers. Biophys J (2013) 0.75
HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts. PLoS One (2016) 0.75
Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia. Eur J Haematol (2014) 0.75
Safety of short-term valacyclovir as an anti-sickling agent in sickle-cell anemia. Pediatr Blood Cancer (2011) 0.75
Sickle cell vaso-occlusive crisis: it's a gut feeling. J Transl Med (2016) 0.75
Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort. Am J Hematol (2016) 0.75
Sickle cell disease. BMJ Clin Evid (2011) 0.75
Synthetic methodology for the preparation of N-hydroxysulfamides. Tetrahedron Lett (2007) 0.75
Common Chemical Inductors of Replication Stress: Focus on Cell-Based Studies. Biomolecules (2017) 0.75
Developing new pharmacotherapeutic approaches to treating sickle-cell disease. ISBT Sci Ser (2016) 0.75
Current concepts in the management of stroke in children with sickle cell disease. Childs Nerv Syst (2011) 0.75
Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med (1994) 15.82
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med (1995) 13.59
Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med (2001) 6.27
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis (1987) 5.63
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med (1999) 5.05
Self-reported antiretroviral therapy in injection drug users. JAMA (1998) 4.75
Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med (1995) 4.42
Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr (2001) 3.67
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis (1992) 3.61
Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med (1995) 3.44
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood (1992) 3.09
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood (1995) 2.82
Longitudinal changes in physical activity in a biracial cohort during adolescence. Med Sci Sports Exerc (2000) 2.75
Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood (1997) 2.74
Net costs from three perspectives of using low versus high osmolality contrast medium in diagnostic angiocardiography. J Am Coll Cardiol (1993) 2.72
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood (1999) 2.66
Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol (1988) 2.60
Impact of timing of pubertal maturation on growth in black and white female adolescents: The National Heart, Lung, and Blood Institute Growth and Health Study. J Pediatr (2001) 2.59
False-positive human immunodeficiency virus screening test related to rabies vaccination. Arch Pathol Lab Med (1994) 2.59
Knowledge, attitudes, and reported practices of medical students and house staff regarding the diagnosis and treatment of alcoholism. JAMA (1989) 2.56
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood (1997) 2.55
Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med (1984) 2.54
Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med (1993) 2.50
Potential factors affecting adherence with HIV therapy. AIDS (1997) 2.44
The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis (1984) 2.44
Characteristics, diagnosis, and treatment of alcoholism in elderly patients. J Am Geriatr Soc (1989) 2.43
Renal abnormalities in sickle cell disease. Am J Hematol (2000) 2.40
Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood (1990) 2.38
Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation (1991) 2.33
Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA (2000) 2.25
Moderate alcohol consumption and coronary artery disease. A review. Medicine (Baltimore) (1986) 2.22
Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med (1999) 2.17
Race, socioeconomic status, and obesity in 9- to 10-year-old girls: the NHLBI Growth and Health Study. Ann Epidemiol (1996) 2.17
A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med (2001) 2.15
Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med (1980) 2.14
Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med (1989) 2.13
Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant (2012) 2.12
Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (1999) 2.08
Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. JAMA (1991) 2.08
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation (2000) 2.07
Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med (1995) 2.05
Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis (1995) 2.01
31P NMR studies of intracellular free Mg2+ in intact frog skeletal muscle. J Biol Chem (1980) 2.01
Origin of the beta S-globin gene in blacks: the contribution of recurrent mutation or gene conversion or both. Proc Natl Acad Sci U S A (1984) 2.00
Racial divergence in adiposity during adolescence: The NHLBI Growth and Health Study. Pediatrics (2001) 2.00
NMR studies of intracellular metal ions in intact cells and tissues. Annu Rev Biophys Bioeng (1984) 1.97
Cryptosporidiosis in patients with AIDS: correlates of disease and survival. Clin Infect Dis (1998) 1.97
Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest (1982) 1.93
Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.89
Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS (2001) 1.88
Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med (1994) 1.87
Neonatal screening for sickle cell disease: a cost-effectiveness analysis. J Pediatr (1991) 1.81
Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort. HIV Med (2008) 1.74
Impact of opportunistic disease on survival in patients with HIV infection. AIDS (1998) 1.71
Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med (2001) 1.68
Alcohol abuse: comparison of two methods for assessing its prevalence and associated morbidity in hospitalized patients. Am J Med (1991) 1.66
Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med (1990) 1.63
Guidelines for quality assurance in multicenter trials: a position paper. Control Clin Trials (1998) 1.60
Predictors of outpatient treatment retention: patient versus substance use characteristics. Drug Alcohol Depend (2001) 1.60
HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS (2001) 1.60
Individual variation in the production and survival of F cells in sickle-cell disease. N Engl J Med (1978) 1.59
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med (1991) 1.58
The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications. Chest (1998) 1.58
Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis (1996) 1.58
Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med (1984) 1.57
Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team. Chest (1998) 1.57
Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis. Results from The TIMI II Study. Circulation (1995) 1.56
Ischemic, hemodynamic, and neurohormonal responses to mental and exercise stress. Experience from the Psychophysiological Investigations of Myocardial Ischemia Study (PIMI). Circulation (1996) 1.55
The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. Chest (1995) 1.53
A prospective investigation of pulmonary embolism in women and men. JAMA (1992) 1.52
Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis (1984) 1.52
F-cell production in sickle cell anemia: regulation by genes linked to beta-hemoglobin locus. Science (1981) 1.51
Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate. Exp Hematol (1992) 1.50
Pulmonary embolism and mortality in patients with COPD. Chest (1996) 1.49
Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med (2005) 1.49
Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med (1990) 1.47
Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation (2001) 1.46
Erythropoietin for anemia of renal failure in sickle cell disease. N Engl J Med (1991) 1.46
Prevention of opportunistic infections in the era of improved antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.46
Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis (1998) 1.45
Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. J Infect Dis (1995) 1.45
Pulmonary hypertension in sickle cell disease. Am J Cardiol (1994) 1.44
Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood (1986) 1.43
Effect of beta-globin gene cluster haplotype on the hematological and clinical features of sickle cell anemia. Am J Hematol (1991) 1.43
Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections. Int J Infect Dis (2006) 1.43
A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion (1998) 1.42